REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Engineered immune cells injected into the brain show promise for deadliest childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and other hard-to-treat brain tumors. The therapy uses the patient's own immune cells, modified in a lab to target four different…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with hard-to-treat cancers: targeted pill attacks faulty gene pathway
Disease control OngoingThis study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC